ENHANCED EXPANSION OF TUMOR-INFILTRATING LYMPHOCYTES FOR ADOPTIVE CELL THERAPY

Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocy...

Full description

Saved in:
Bibliographic Details
Main Authors WEBER, JEFFREY S, PILON-THOMAS, SHARI, RADVANYI, LASZLO G, SARNAIK, AMOD A, MULÉ, JAMES J, CHACON, JESSICA ANN
Format Patent
LanguageEnglish
French
Published 15.10.2015
Subjects
AGRICULTURE
ANIMAL HUSBANDRY
BEER
BIOCHEMISTRY
BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
FISHING
FORESTRY
HUMAN NECESSITIES
HUNTING
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PEST REPELLANTS OR ATTRACTANTS
PLANT GROWTH REGULATORS
PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTSTHEREOF
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
TRAPPING
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods. L'invention concerne un procédé d'expansion ex vivo des lymphocytes infiltrants des tumeurs, destinés à être utilisés dans le cadre de la thérapie cellulaire adoptive (ACT). Le procédé consiste à cultiver des fragments de tumeurs provenant du sujet, dans un milieu de culture contenant les agonistes IL-2 et 41 BB, dans une quantité efficace pour amplifier des lymphocytes infiltrant les tumeurs ayant une réactivité et une spécificité tumorales améliorées. L'invention concerne également un procédé de traitement d'une tumeur chez un sujet qui consiste à traiter ce sujet par chimiothérapie non myéloablative appauvrissant les lymphocytes, et à administrer des lymphocytes infiltrant des tumeurs amplifiés par les procédés de l'invention.
Bibliography:Application Number: WO2015US25313